| 词条 | George Siber |
| 释义 |
}}{{Infobox scientist | name = George R. Siber | native_name = | native_name_lang = | image = George Siber 2014.png | image_size = | alt = | caption = | birth_date = {{Birth date|1944|09|07}} | birth_place = Bavaria | death_date = | death_place = | resting_place = | resting_place_coordinates = | other_names = | residence = | citizenship = Canadian and American (dual) | nationality = | fields = Vaccinology | workplaces = | patrons = | alma_mater = McGill University | thesis_title = | thesis_url = | thesis_year = | doctoral_advisor = David Hamilton Smith and Porter Anderson[1] | academic_advisors = | doctoral_students = | notable_students = Donna Ambrosino,[2] Shaw Warren,[3] and John Schreiber[4] | known_for = | author_abbrev_bot = | author_abbrev_zoo = | influences = John Franklin Enders,[5] Porter Anderson,[6] David Hamilton Smith,[7] John Robbins, Robert Austrian, Maurice Hilleman | influenced = | awards = | signature = | signature_alt = | website = | footnotes = | spouse = {{marriage|Angelia Siber|2006}} | children = }} George Rainer Siber (born September 7, 1944) is an internationally recognized medical researcher and vaccine expert with {{age|1975|06|20}} years of experience in developing numerous vaccines, therapeutic antibodies, and diagnostic agents for infectious diseases. Siber is a former Harvard professor, current Adjunct Professor at Johns Hopkins University and Professor at the University of Massachusetts Medical School, former Executive Vice President and Chief Science Officer of Wyeth (developer of Prevnar, Meningitec, Rotashield, and FluMist), and Advisory Committee member of the World Health Organization, US National Institutes of Health, Gates Foundation, and the National Institute of Allergy and Infectious Diseases.[8][9] BiographyEarly life & educationSiber emigrated from Bavaria, Germany with his parents at age nine in 1953 to Montreal. At the time, he spoke no English. Later, he attended Chambly Academy where he graduated in 1962. It was at Chambly, which later become Penfield Academy, that Siber was convinced by Wilder Penfield to pursue a career in medicine.[10] After high school, he attended Bishop's University in Lennoxville, Quebec from 1962 to 1966 where he graduated with honors and obtained a Bachelor of Science. Siber then attended McGill University in Montreal, Quebec, Canada where he became a Doctor of Medicine in 1970. It was during this time that Siber published research he completed at the Montreal Neurological Institute.[11] Siber is both a US and Canadian citizen. He has homes in Manhattan and Beijing. Interships, residencies, and fellowshipsAfter graduation in 1970, Siber held several internships, residencies, and fellowships. Between 1970 and 1972, Siber worked in Chicago as an intern and Junior Medical Resident at Rush University Medical Center. In 1972, Siber moved to Boston and worked as a Senior Medical Resident and clinical fellow in medicine at Beth Israel Hospital until 1973. Between 1973 and 1975, Siber worked as a clinical fellow in infectious diseases and research fellow in medicine at Beth Israel Hospital, Boston Children's Hospital, and Harvard Medical School. Between 1974 and 1975, Siber was also a fellow for the Medical Research Council of Canada.[12] Professional experienceIndustry appointmentsGeorge Siber has held several industry appointments for various companies since the mid 90s. Siber served as the Vice President, Chief Scientific Officer, and Senior Vice President, and Executive Vice President for Wyeth from 1996 to 2006.[12] Wyeth was then purchased by Pfizer in 2009. While at Wyeth, Siber oversaw the development and approval of several often used vaccines for children, including Prevnar, a pneumococcal vaccine, Acel-Imune, an acellular pertussis vaccine, Meningitec, a meningococcal meningitis vaccine, Rotashield, a rotavirus vaccine, and FluMist, a nasal spray influenza vaccine.[13][14] Since retiring from Wyeth Siber has served on the Boards of Directors of several companies, Since 2007, Siber has served as the Executive Chairman (until 2013) and as Executive Director and Chairman of the Scientific Advisory Board for Genocea Biosiences in Cambridge, Massachusetts. In 2009 he was appointed as the Director of Selecta Biosciences in Watertown, Massachusetts. In 2012 he joined the Board of Directors and SAB of Vedantra Parmaceutcals and the Board of Huamei Biotechnologies, also known as Sino-American Biotechnology Company (SABC), in Luoyang, China. In 2014 he co-founded Affinivax together with Richard Malley, Fan Zhang, Yingjie Lu, Steve Brugger, and Kamran Tavangar with seed funding from the Bill and Melinda Gates Foundation, and serves on the Board of Directors.[12][15][16][19][17][18][19] Siber joined ClearPath Vaccine Company in 2012 and became its Chief Scientific Officer in 2013.[12] Siber was appointed to the Board of Trustees of the International Vaccine Institute in Korea in 2014 and chairs the Board's Science Committee.[24][25] Siber has served on numerous scientific advisory committees including Variation Biotechnologies in Cambridge (2008–09), Ligocyte Pharmaceuticals in Bozeman, Missouri (2008–12), Ancora Pharmaceuticals Medford, Massachusetts (2008–12), Prothena Biosciences (previously Neotope) in San Francisco (2009–present), Visterra Inc in Cambridge (2011–14), AbVitro in Boston (2013–present), Vaxess in Cambridge (2014 – present) PaxVax in San Diego (2014–present), and Veritas Gene (2014–present). Siber also serves on the External Advisory Board of Aditec on behalf of the EC (2009 – present), the Korean FDA, (2011–present) and the Vaccine Advisory Committee of the Wistar Institute in Philadelphia (2012–present). Department of Public Health appointmentsGeorge Siber served as the Assistant Director and Head of Bacterial Vaccines for the Massachusetts Public Health Biological Laboratories in Jamaica Plain, Massachusetts between 1982 and 1983. In 1983, he was promoted to the position of Director where he served until 1996. Academic appointmentsSince 1975, Siber has held several academic appointments and teaching positions. Siber has held positions at Harvard Medical School (Associate Professor until 1996), Tufts University School of Medicine, University of Massachusetts Medical School (Professor of Medicine until 2012), and the Johns Hopkins Bloomberg School of Public Health (Adjunct Professor from 2008 to present).[12][12][20] Between 1975 ad 1996, Siber held several hospital appointments at various hospitals including Beth Israel Hospital, the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Newton-Wellesley Hospital, Mouth Auburn Hospital, Harvard University Health Services, and the Children's Hospital. He served as an assistant physician, associate in medicine, and as courtesy staff across those locations.[12] Products developed and licenses for marketing and saleSiber has been directly involved in the creation of several products, most of which were created while working for Wyeth and Mass Biologics. Siber holds patents on Bactogen, a diagnostic kit for bacterial meningitis, RespiGam, the first Human respiratory syncytial virus immune globulin, and Prevnar, the first Pneumococcal Pneumonia Conjugate.[21] Respigam was the first antibody licensed for preventing severe RSV infections in high-risk infants and was the precursor product to Synagis, the first human monoclonal antibody for infectious diseases. Prevnar 7 and 13 are for the prevention of pneumococcal infections, the most common and severe bacterial infection of children and elderly adults worldwide causing mortality exceeding 1 million per year. Prevnar is also the most successful commercial vaccine of all time with sales exceeding four billion dollars per year. Siber also developed Cytogam, the first Cytomegalovirus immune Globulin, BabyBIG, the first infant botulism immune globulin, the Haemophilus influenzae conjugate vaccine in Quinvaxim licensed to Berna, Acellimune, an Acellular pertussis combination vaccine, Meningitex, the first Meningoccus C conjugate vaccine, Rotashield, the first Rotavirus diarrhea vaccine, and FluMist, the first Live attenuated influenza vaccine.[12][22][21][23] Siber became a Diplomate with the National Board of Medical Examiners in 1971, a Diplomate with the American Board of Internal Medicine in 1973, and a Diplomate in Infectious Diseases for the American Board of Internal Medicine. Awards
Patents
References1. ^{{cite news|title=Vaccine Technology Takes Center Stage in Rochester|url=http://www.urmc.rochester.edu/news/story/index.cfm?id=-607|accessdate=7 July 2014|publisher=University of Rochester Medical Center|date=1998-10-08}} {{portal|Biology|Health|Medicine}}2. ^{{cite web|title=National distinction in health sciences education research and public service |url=http://www.umassmed.edu/Content.aspx?id=45482 |publisher=University of Massachusetts |accessdate=7 July 2014 |deadurl=yes |archiveurl=https://web.archive.org/web/20140819091125/http://www.umassmed.edu/Content.aspx?id=45482 |archivedate=19 August 2014 |df= }} 3. ^{{cite web|title=Professional Profile of Shaw Warren|url=http://www.biomedexperts.com/Profile.bme/1517244/H_Shaw_Warren|publisher=BiomedExperts|accessdate=7 July 2014}} 4. ^{{cite journal|last1=Reichler|first1=M. R.|last2=Allphin|first2=A. A.|last3=Breiman|first3=R. F.|last4=Schreiber|first4=J. R.|last5=Arnold|first5=J. E.|last6=McDougal|first6=L. K.|last7=Facklam|first7=R. R.|last8=Boxerbaum|first8=B.|last9=May|first9=D.|last10=Walton|first10=R. O.|last11=Jacobs|first11=M. R.|title=The Spread of Multiply Resistant Streptococcus pneumoniae at a Day Care Center in Ohio|journal=Journal of Infectious Diseases|date=1 December 1992|volume=166|issue=6|pages=1346–1353|doi=10.1093/infdis/166.6.1346|url=http://jid.oxfordjournals.org/content/166/6/1346.short|accessdate=7 July 2014}} 5. ^{{cite web|title=Part of Team that Created Remarkable Hib Vaccine|url=http://www.scienceheroes.com/index.php?option=com_content&view=article&id=249&Itemid=225|publisher=Science Heroes|accessdate=7 July 2014}} 6. ^{{cite news|last1=Pearson|first1=David|title=The Problem Solver|url=http://www.emory.edu/EMORY_MAGAZINE/issues/2011/spring/features/anderson.html|accessdate=7 July 2014|publisher=EMORY Magazine|date=Spring 2011}} 7. ^{{cite web|title=Albert Lasker Clinical Medical Research Award - 1996|url=http://www.laskerfoundation.org/awards/1996clinical.htm|publisher=Lasker Foundation|accessdate=8 July 2014|deadurl=yes|archiveurl=https://web.archive.org/web/20140116111726/http://www.laskerfoundation.org/awards/1996clinical.htm|archivedate=16 January 2014|df=}} 8. ^{{cite web|title=ClearPath Development Team|url=http://www.clearpathdevco.com/?page_id=216|publisher=ClearPath Development Company|accessdate=7 July 2014}} 9. ^{{cite web|last1=Clark|first1=Thornton|title=Porter Anderson|url=http://www.encyclopediaofalabama.org/face/Article.jsp?id=h-3336|publisher=The Encyclopedia of Alabama|accessdate=7 July 2014}} 10. ^{{cite web|title=Chambly County High School & Chambly Academy Alumni Association |url=http://www.chamblycounty.com/Alumni%20connection%20August%202013.html |publisher=Chambly County |accessdate=2 April 2014 |deadurl=yes |archiveurl=https://web.archive.org/web/20140903063114/http://www.chamblycounty.com/Alumni%20connection%20August%202013.html |archivedate=3 September 2014 |df= }} 11. ^{{cite journal|last=Sherwin|first=A.L.|author2=Siber, G.R. |author3=Elhilali, M.M. |title=Fluorescence technique to demonstrate creatine phosphokinase isozymes|journal=Clinica Chimica Acta|date=August 1967|volume=17|issue=2|pages=245–249|doi=10.1016/0009-8981(67)90127-1}} 12. ^1 2 3 4 5 6 7 {{cite web|title=14th Annual World Vaccine Congress 2014|url=http://www.terrapinn.com/conference/world-vaccine-congress-washington/speaker-george-SIBER.stm|publisher=Terrapinn Holdings|accessdate=21 March 2014}} 13. ^{{cite news|title=Astellas To Form Strategic Partnership With Clearpath To Build Vaccine Portfolio-In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics-|url=http://www.astellas.com/en/corporate/news/detail/astellas-to-form-strategic-par.html|accessdate=2 April 2014|newspaper=Astellas|date=2014-01-06}} 14. ^{{cite news|title=Genocea Biosciences Appoints Katrine Bosley As Chairman Of The Board Of Directors; Vaccine Industry Leader George Siber, M.D. To Serve As Executive Director And Head Of Scientific Advisory Board|url=http://www.bizjournals.com/prnewswire/press_releases/2013/11/18/NE18716|accessdate=24 March 2014|newspaper=BizJournals|date=2013-11-18}} 15. ^{{cite news|last=Crawford|first=Steve|title=Dr. George Siber Joins Ancora Pharmaceuticals Scientific|url=https://www.bloomberg.com/apps/news?pid=conewsstory&tkr=WYE:US&sid=apT190JL1FMQ|accessdate=20 March 2014|newspaper=Bloomberg|date=2010-10-28}} 16. ^{{cite web|title=Selecta Board of Directors |url=http://www.selectabio.com/company/board-of-directors.cfm |publisher=Selecta Biosciences |accessdate=24 March 2014 |deadurl=yes |archiveurl=https://web.archive.org/web/20131207012211/http://selectabio.com/company/board-of-directors.cfm |archivedate=7 December 2013 |df= }} 17. ^1 {{cite web|title=External Advisory Board - Dr George Siber|url=http://www.aditecproject.eu/about-aditec/external-advisory-board/dr-george-siber.html|publisher=Aditec|accessdate=20 March 2014}} 18. ^{{cite web|title=Vaccine Industry Leader George Siber, M.D. Joins Vaxess Technologies As Chairman Of Scientific Advisory Board|url=http://www.vaxess.com/wp-content/uploads/2014/02/George-Siber-to-Chair-Vaxess-SAB-Final.pdf|publisher=Vaxess Technologies|accessdate=20 March 2014}} 19. ^{{cite web |title=Prothena Scientific Advisory Board |url=http://www.prothena.com/company/scientific-advisory-board/ |publisher=Prothena |accessdate=24 March 2014 |deadurl=yes |archiveurl=https://web.archive.org/web/20140309044209/http://www.prothena.com/company/scientific-advisory-board/ |archivedate=9 March 2014 |df= }} 20. ^{{cite web|title=George Siber, MDCM |url=http://www.jhsph.edu/faculty/directory/profile/-2023/Siber/George |publisher=Johns Hopkins Bloomberg School of Public Health |accessdate=24 March 2014 |deadurl=yes |archiveurl=https://web.archive.org/web/20140911001837/http://www.jhsph.edu/faculty/directory/profile/-2023/Siber/George |archivedate=11 September 2014 |df= }} 21. ^1 2 {{cite web|title=Genocea Prospectus|url=http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=9316711|publisher=NASDAQ|accessdate=9 July 2014}} 22. ^1 {{cite web|title=Scientific Team |url=http://www.affinivax.com/founders/ |publisher=Affinivax |accessdate=9 July 2014 |deadurl=yes |archiveurl=https://web.archive.org/web/20140910201547/http://www.affinivax.com/founders/ |archivedate=10 September 2014 |df= }} 23. ^{{cite news|title=Genocea Biosciences Inc (GNCA:NASDAQ GM)|url=http://investing.businessweek.com/research/stocks/people/person.asp?personId=35221936&ticker=GNCA|accessdate=9 July 2014|publisher=BusinessWeek|date=07/08/2014}} BibliographyJournals{{cleanup list|section|date=August 2018}}
Books
External links
15 : 1944 births|Living people|Vaccinologists|American immunologists|Canadian immunologists|American virologists|American infectious disease physicians|Canadian infectious disease physicians|Harvard Medical School faculty|Tufts University faculty|Johns Hopkins University faculty|Bishop's University alumni|McGill University alumni|People from Boston|People from Bavaria |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。